DNLI vs MGTX
DNLI: Denali Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary platform to transport large-molecule medicines across the blood-brain barrier for the treatment of neurodegenerative diseases and rare disorders. MGTX: A vertically integrated clinical-stage genetic medicines company developing locally-delivered gene therapies for ophthalmology, Parkinson's disease, and xerostomia, backed by proprietary viral vector manufacturing and riboswitch gene regulation technology.
Side-by-side fundamentals
| Metric | DNLI | MGTX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $23.57 | $12.30 | |
| Market cap as of 2026-07-30 | $3.8B | $1.1B | |
| PEG as of 2026-07-30 | -1.06 | n/a | |
| Net margin as of 2026-07-30 | -36.5% | -151.1% | DNLI higher |
| Gross margin as of 2026-07-30 | n/a | +95.4% | |
| Operating margin as of 2026-07-30 | -49.7% | -131.9% | DNLI higher |
| ROE as of 2026-07-30 | -50.1% | -315.6% | DNLI higher |
| ROA as of 2026-07-30 | -44.2% | -55.0% | DNLI higher |
| Debt / equity as of 2026-07-30 | 0.01 | 24.92 | DNLI lower |
| Revenue growth (YoY) as of 2026-07-30 | n/a | +131.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +141.0% | |
| Beta as of 2026-07-30 | 0.99 | 1.28 | |
| 1-year return as of 2026-07-27 close | +72.4% | +47.0% | DNLI higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.